D-Index & Metrics Best Publications

Roxana Mehran

Icahn School of Medicine at Mount Sinai
United States

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 166 Citations 134,999 1,950 World Ranking 331 National Ranking 213

Best female scientists D-index 166 Citations 134,999 1,954 World Ranking 46 National Ranking 33

Best Scientists D-index 166 Citations 134,999 1,954 World Ranking 653 National Ranking 421

Research.com Recognitions

Awards & Achievements

2023 - Research.com Best Female Scientist Award

2023 - Research.com Best Scientist Award

2022 - Research.com Best Female Scientist Award

2022 - Research.com Best Scientist Award

Overview

What is she best known for?

The fields of study Roxana Mehran is best known for:

Warfarin
Kidney disease
Diabetes mellitus

Her research ties Kidney disease and Internal medicine together. She performs multidisciplinary study in Kidney disease and Contrast-induced nephropathy in her work. Her study in Conventional PCI extends to Cardiology with its themes. Her research on Conventional PCI often connects related topics like Myocardial infarction. In her study, she carries out multidisciplinary Myocardial infarction and Antithrombotic research. Antithrombotic and Cardiology are frequently intertwined in her study. Her work on Percutaneous coronary intervention is being expanded to include thematically relevant topics such as Contrast-induced nephropathy. Her study in Artificial intelligence extends to Contrast (vision) with its themes. Many of her studies involve connections with topics such as Contrast (vision) and Artificial intelligence.

Her most cited work include:

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation (705 citations)
Contrast-induced nephropathy: Definition, epidemiology, and patients at risk (621 citations)
A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary interventionDevelopment and initial validation (67 citations)

What are the main themes of her work throughout her whole career to date

Cancer is connected with Oncology and Esophageal cancer in her research. She integrates Oncology with Cancer in her study. Many of her studies on Internal medicine involve topics that are commonly interrelated, such as Radiation therapy. She conducts interdisciplinary study in the fields of Myocardial infarction and Acute coronary syndrome through her works. Her study connects Thrombus and Cardiology. Her studies link Cardiology with Thrombus. Percutaneous coronary intervention and Bivalirudin are frequently intertwined in her study. Roxana Mehran regularly ties together related areas like Percutaneous coronary intervention in her Bivalirudin studies. Roxana Mehran performs integrative study on Randomized controlled trial and Myocardial infarction in her works.

Roxana Mehran most often published in these fields:

Internal medicine (100.00%)
Myocardial infarction (52.94%)
Cardiology (47.06%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Clinical End Points in Coronary Stent Trials A Case for Standardized Definitions

Donald E. Cutlip;Stephan Windecker;Roxana Mehran;Ashley Boam.
Circulation (2007)

5654 Citations

Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document.

A. Pieter Kappetein;Stuart J. Head;Philippe Généreux;Nicolo Piazza.
The Journal of Thoracic and Cardiovascular Surgery (2012)

5414 Citations

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions

Glenn N. Levine;Eric R. Bates;James C. Blankenship;Steven R. Bailey.
Circulation (2011)

5065 Citations

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.

Morteza Naghavi;Peter Libby;Erling Falk;S. Ward Casscells;S. Ward Casscells.
Circulation (2003)

4582 Citations

Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium

Roxana Mehran;Sunil V. Rao;Deepak L. Bhatt;C. Michael Gibson.
Circulation (2011)

3432 Citations

A Prospective Natural-History Study of Coronary Atherosclerosis

Gregg W. Stone;Akiko Maehara;Alexandra J. Lansky;Bernard de Bruyne.
The New England Journal of Medicine (2011)

2968 Citations

A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation

Roxana Mehran;Eve D. Aymong;Eugenia Nikolsky;Zoran Lasic.
Journal of the American College of Cardiology (2004)

2715 Citations

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

Glenn N. Levine;Eric R. Bates;James C. Blankenship;Steven R. Bailey.
Journal of the American College of Cardiology (2011)

2687 Citations

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents

Gregg W. Stone;Jeffrey W. Moses;Stephen G. Ellis;Joachim Schofer.
The New England Journal of Medicine (2007)

2149 Citations

Bivalirudin during Primary PCI in Acute Myocardial Infarction

Gregg W. Stone;Bernhard Witzenbichler;Giulio Guagliumi;Jan Z. Peruga.
The New England Journal of Medicine (2008)

2130 Citations

If you think any of the details on this page are incorrect, let us know.

Frequent Co-Authors

External Links

Personal Website for Roxana Mehran